PB 118 of 2025
National Health (Minimum Stockholding) Amendment Determination (No. 9) 2025
I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.
Dated 25 September 2025
Rebecca Richardson
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name...................................................1
2 Commencement............................................1
3 Authority................................................1
4 Schedules................................................1
Schedule 1—Amendments commencing 1 October 2025 2
National Health (Minimum Stockholding) Determination 2023 2
Schedule 2—Amendments commencing immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025 – 1 October 2025 18
National Health (Minimum Stockholding) Determination 2023 18
Schedule 3—Amendments commencing immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 6) 2025 – 1 October 2025 19
National Health (Minimum Stockholding) Determination 2023 19
Schedule 4—Amendments commencing immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 5) 2025 – 1 November 2025 21
National Health (Minimum Stockholding) Determination 2023 21
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 9) 2025.
(2) This instrument may also be cited as PB 118 of 2025.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 October 2025. | 1 October 2025 |
2. Schedule 1 | 1 October 2025. | 1 October 2025 |
3. Schedule 2 | Immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025. | 1 October 2025 |
4. Schedule 3 | Immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 6) 2025. | 1 October 2025 |
5. Schedule 4 | Immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 5) 2025. | 1 November 2025 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Schedule 1 (table)
Omit:
Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | Kivexa | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
2 Schedule 1 (table)
Omit:
Aciclovir | Tablet 200 mg | Oral | Aciclovir APOTEX | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |
3 Schedule 1 (table)
Omit:
Allopurinol | Tablet 100 mg | Oral | NOUMED ALLOPURINOL | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
4 Schedule 1 (table)
Omit:
Amino acid formula with vitamins and minerals without lysine and low in tryptophan | Sachets containing oral powder 24 g, 30 (GA gel) | Oral | GA gel | 0 months stock by reference to usual PBS demand |
5 Schedule 1 (table)
After:
Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | 4.5 months stock by reference to usual demand |
insert:
Amlodipine | Tablet 10 mg (as besilate) | Oral | APX-AMLODIPINE | after 31 January 2026—6 months stock by reference to usual demand of both APX-AMLODIPINE and Amlodipine APOTEX added together |
6 Schedule 1 (table)
Omit:
Amlodipine | Tablet 10 mg (as besilate) | Oral | NOUMED AMLODIPINE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
7 Schedule 1 (table)
Omit:
Amlodipine | Tablet 5 mg (as besilate) | Oral | NOUMED AMLODIPINE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
Amoxicillin | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | NOUMED AMOXICILLIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
8 Schedule 1 (table)
After:
Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |
insert:
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Alphaclav Duo Viatris | after 31 December 2025—6 months stock by reference to usual demand of both Alphaclav Duo Viatris and AlphaClav Duo added together |
9 Schedule 1 (table)
After:
Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
insert:
Atazanavir | Capsule 200 mg (as sulfate) | Oral | Reyataz | between 1 October 2025 to 30 June 2026—0 months stock by reference to usual demand |
Atazanavir | Capsule 300 mg (as sulfate) | Oral | Reyataz | between 1 October 2025 to 30 June 2026—0 months stock by reference to usual demand |
10 Schedule 1 (table)
Omit:
Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral | NOUMED BISOPROLOL | between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand |
Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | NOUMED BISOPROLOL | between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand |
Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | NOUMED BISOPROLOL | between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand |
11 Schedule 1 (table)
After:
Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
insert:
Carboplatin | Solution for I.V. injection 450 mg in 45 mL | Injection | Carboplatin Accord | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
12 Schedule 1 (table)
Omit:
Cefalexin | Capsule 500 mg (as monohydrate) | Oral | NOUMED CEFALEXIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
13 Schedule 1 (table)
Omit:
Ciprofloxacin | Tablet 500 mg (as hydrochloride) | Oral | NOUMED CIPROFLOXACIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
Ciprofloxacin | Tablet 750 mg (as hydrochloride) | Oral | NOUMED CIPROFLOXACIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | NOUMED CITALOPRAM | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
14 Schedule 1 (table)
After:
Doxorubicin ‑ pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
insert:
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | 4 months stock by reference to usual demand |
Doxycycline | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | 4 months stock by reference to usual demand |
15 Schedule 1 (table)
After:
Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | Transdermal | Estalis continuous 50/140 | 6 months stock by reference to usual PBS demand |
insert:
Ezetimibe with atorvastatin | Tablet 10 mg-10 mg | Oral | Atozet | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Ezetimibe with atorvastatin | Tablet 10 mg-10 mg | Oral | Ezetast | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Ezetimibe with atorvastatin | Tablet 10 mg-10 mg | Oral | Ezetimibe/Atorvastatin GH 10/10 | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Ezetimibe with atorvastatin | Tablet 10 mg-20 mg | Oral | Atozet | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Ezetimibe with atorvastatin | Tablet 10 mg-20 mg | Oral | Ezetast | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Ezetimibe with atorvastatin | Tablet 10 mg-20 mg | Oral | Ezetimibe/Atorvastatin GH 10/20 | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
16 Schedule 1 (table)
After:
Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 12.6 mg | Transdermal | Fentanyl Sandoz | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
17 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 12.6 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 16.8 mg | Transdermal | Fentanyl Sandoz | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
18 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO‑Fentanyl | 3.5 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 2.1 mg | Transdermal | Fentanyl Sandoz | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
19 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 4.2 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 4.2 mg | Transdermal | Fentanyl Sandoz | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
20 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 8.4 mg | Transdermal | Fentanyl Sandoz | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
21 Schedule 1 (table)
After:
Ferrous Sulfate | Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL | Oral | Ferro-Liquid | 6 months stock by reference to usual PBS demand |
insert:
Flucloxacillin | Powder for injection 1 g (as sodium monohydrate) | Injection | Flucil | between 1 October 2025 to 30 November 2025—0 months stock by reference to usual demand |
22 Schedule 1 (table)
After:
Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 | 4 months stock by reference to usual PBS demand |
insert:
Folinic acid | Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL | Injection | Leucovorin Calcium (Pfizer Australia Pty Ltd) | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
23 Schedule 1 (table)
Omit:
Glyceryl trinitrate | Transdermal patch 36 mg | Transdermal | Minitran 10 | between 1 February 2025 and 30 September 2025—0 months stock by reference to usual demand |
24 Schedule 1 (table)
Omit:
Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib-APOTEX | 3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together |
25 Schedule 1 (table)
Omit:
Naloxone | Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe | Injection | Prenoxad | between 1 April 2025 and 30 September 2025—4 months stock by reference to usual demand |
26 Schedule 1 (table)
Omit:
Nevirapine | Tablet 400 mg (extended release) | Oral | Viramune XR | between 1 October 2024 and 30 September 2025—0 months stock by reference to usual demand |
27 Schedule 1 (table)
After:
Oxybutynin | Transdermal patches 36 mg, 8 | Transdermal | Oxytrol | 6 months stock by reference to usual PBS demand |
insert:
Oxycodone | Capsule containing oxycodone hydrochloride 10 mg | Oral | Oxycodone BNM | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Oxycodone | Capsule containing oxycodone hydrochloride 10 mg | Oral | OxyNorm | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Oxycodone | Capsule containing oxycodone hydrochloride 20 mg | Oral | Oxycodone BNM | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Oxycodone | Capsule containing oxycodone hydrochloride 20 mg | Oral | OxyNorm | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
28 Schedule 1 (table)
Omit:
Oxycodone | Tablet containing oxycodone hydrochloride 5 mg | Oral | Oxycodone Viatris | 6 months stock by reference to usual demand |
29 Schedule 1 (table)
After:
Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL | Oral | OxyNorm Liquid 1mg/mL | 4 months stock by reference to usual PBS demand |
insert:
Pamidronic acid | Concentrated injection containing pamidronate disodium 15 mg in 5 mL | Injection | Pamisol | between 1 October 2025 to 31 January 2026—0 months stock by reference to usual demand |
Pamidronic acid | Concentrated injection containing pamidronate disodium 30 mg in 10 mL | Injection | Pamisol | between 1 October 2025 to 31 January 2026—0 months stock by reference to usual demand |
30 Schedule 1 (table)
Omit:
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
31 Schedule 1 (table)
After:
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | 5.5 months stock by reference to usual demand |
insert:
Pemetrexed | Powder for I.V. infusion 1 g (as disodium) | Injection | Pemetrexed Accord | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
Pemetrexed | Powder for I.V. infusion 1 g (as disodium) | Injection | Pemetrexed SUN | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
32 Schedule 1 (table)
Omit:
Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |
33 Schedule 1 (table)
Omit:
Ramipril with felodipine | Tablet 2.5 mg-2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | between 1 February 2025 and 30 September 2025—0 months stock by reference to usual PBS demand |
34 Schedule 1 (table)
Omit:
Risperidone | Tablet 1 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
35 Schedule 1 (table)
Omit:
Risperidone | Tablet 2 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
36 Schedule 1 (table)
After:
Risperidone | Tablet 0.5 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 November 2025—0 months stock by reference to usual demand |
insert:
Risperidone | Tablet 0.5 mg | Oral | Risperdal | between 1 October 2025 to 31 January 2026—0 months stock by reference to usual demand |
Risperidone | Tablet 1 mg | Oral | Risperdal | between 1 October 2025 to 31 January 2026—0 months stock by reference to usual demand |
Risperidone | Tablet 2 mg | Oral | Risperdal | between 1 October 2025 to 31 January 2026—0 months stock by reference to usual demand |
37 Schedule 1 (table)
Omit:
Risperidone | Tablet 3 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
38 Schedule 1 (table)
Omit:
Risperidone | Tablet 4 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
39 Schedule 1 (table)
After:
Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
insert:
Risperidone | Tablet 3 mg | Oral | Risperdal | between 1 October 2025 to 31 January 2026—0 months stock by reference to usual demand |
Risperidone | Tablet 4 mg | Oral | Risperdal | between 1 October 2025 to 31 January 2026—0 months stock by reference to usual demand |
40 Schedule 1 (table)
After:
Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | 5 months stock by reference to usual demand |
insert:
Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Asmol CFC-Free with dose counter | 4 months stock by reference to usual demand |
41 Schedule 1 (table)
After:
Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Ventolin CFC-Free with dose counter | 4 months stock by reference to usual demand |
insert:
Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Zempreon CFC-Free with dose counter | 4 months stock by reference to usual demand |
42 Schedule 1 (table)
Omit:
Tamoxifen | Tablet 20 mg (as citrate) | Oral | Tamosin | between 1 April 2025 and 30 September 2025—0 months stock by reference to usual demand |
43 Schedule 1 (table)
After:
Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
insert:
Telmisartan with amlodipine | Tablet 40 mg-10 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
Telmisartan with amlodipine | Tablet 40 mg-10 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
Telmisartan with amlodipine | Tablet 40 mg-5 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
Telmisartan with amlodipine | Tablet 40 mg-5 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
Telmisartan with amlodipine | Tablet 80 mg-10 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
Telmisartan with amlodipine | Tablet 80 mg-10 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
Telmisartan with amlodipine | Tablet 80 mg-5 mg (as besilate) | Oral | Pritor/Amlodipine | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
Telmisartan with amlodipine | Tablet 80 mg-5 mg (as besilate) | Oral | Twynsta | between 1 October 2025 to 31 January 2027—0 months stock by reference to usual demand |
44 Schedule 1 (table)
Omit:
Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Viread | between 1 June 2025 and 30 September 2025—2 months stock by reference to usual demand |
45 Schedule 1 (table)
Omit:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | CIPLA TENOFOVIR + EMTRICITABINE 300/200 | between 1 June 2025 and 30 September 2025—4 months stock by reference to usual demand |
46 Schedule 1 (table)
After:
Tobramycin | Injection 80 mg (as sulfate) in 2 mL (without preservative) | Injection | Pfizer Australia Pty Ltd | 2 months stock by reference to usual demand |
insert:
Tobramycin | Solution for inhalation 300 mg in 5 mL | Inhalation | Tobramycin WKT | between 1 October 2025 to 30 November 2025—0 months stock by reference to usual demand |
1 Schedule 1 (table)
After:
Levonorgestrel | Intrauterine drug delivery system 52 mg | Intrauterine | Mirena | 6 months stock by reference to usual PBS demand |
insert:
Lincomycin | Injection 600 mg (as hydrochloride monohydrate) in 2 mL | Injection | Lincocin | between 1 October 2025 to 31 March 2026—0 months stock by reference to usual demand |
1 Schedule 1 (table)
After:
Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |
insert:
Erlotinib | Tablet 100 mg (as hydrochloride) | Oral | Erlotinib APOTEX | after 28 February 2026—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
Erlotinib | Tablet 100 mg (as hydrochloride) | Oral | ERLOTINIB ARX | after 28 February 2026—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
Erlotinib | Tablet 150 mg (as hydrochloride) | Oral | Erlotinib APOTEX | after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
Erlotinib | Tablet 150 mg (as hydrochloride) | Oral | ERLOTINIB ARX | after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
Erlotinib | Tablet 25 mg (as hydrochloride) | Oral | Erlotinib APOTEX | after 31 March 2026—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
Erlotinib | Tablet 25 mg (as hydrochloride) | Oral | ERLOTINIB ARX | after 31 March 2026—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together |
2 Schedule 1 (table)
After:
Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir ARX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |
insert:
Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |
3 Schedule 1 (table)
After:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 ARX | 3 months stock by reference to usual demand |
insert:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine Sandoz 301/200 | between 1 October 2025 and 31 March 2026—4 months stock by reference to usual demand |
1 Schedule 1 (table)
Omit:
Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |